IgA nephropathy
Conditions
Interventions
Immunosuppressive therapy group:NA
Sponsors
Affiliated Hospital of Guangdong Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.From January 1, 2013 to December 31, 2025, patients who were 18 years old or older in the Department of Nephrology of the Affiliated Hospital of Guangdong Medical University, confirmed to have IgA nephropathy by renal biopsy, and the clinical and pathological data were kept intact, and the urine protein was completely relieved for at least 3 months after immunosuppressive therapy, and the follow-up was = for 3 years.
Exclusion criteria
Exclusion criteria: 1. Systemic diseases that may lead to secondary renal IgA deposition, such as chronic hepatitis virus infection, human immunodeficiency virus (HIV) infection, autoimmune diseases including systemic lupus erythematosus (SLE), allergic purpura nephritis (HSPN), Sjögren's syndrome (SS), ankylosing spondylitis (AS), etc. 2.(2) Patients with crescent nephritis (>50% of patients with pathological diagnosis), minimal change nephropathy with IgA deposition and other types of glomerular diseases; 3.(2) Transplanted kidney or combined with other pathological types, such as minimal lesions, membranous nephropathy, diabetic nephropathy, etc. 4.?(3) There are comorbidities that affect treatment, such as malignant tumors, pregnancy, severe malnutrition, etc. 5.(4) Severe infection, serious gastrointestinal complications or other reasons that make it impossible to receive oral medication; 6.(5) Patients with IgA nephropathy in stage 5 CKD.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Urinary protein recurrence rate within 3 years; | — |
Secondary
| Measure | Time frame |
|---|---|
| Renal combined endpoint events; | — |
Countries
China
Contacts
Public ContactLuo Mianna
Affiliated Hospital of Guangdong Medical University
Outcome results
None listed